Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia

References

• Casali PG, Jost L, Sleijfer S, et al. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol Off J ESMO 2008;19(2 Suppl):ii89-93
   PubMedGoogle Scholar
• Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol Off J Am Soc Clin Oncol 2000;18:2676-84
   PubMed Web of Science ®Google Scholar
• Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol Off J ESMO 2013;24:1703-9
   PubMed Web of Science ®Google Scholar
• Jelic S, Kovcin V, Milanovic N, et al. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997;33:220-5
   PubMed Web of Science ®Google Scholar
• O'Brien S, Radich J, Abboud C, et al. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw 2013;11(11):1327-40
   PubMed Web of Science ®Google Scholar
• Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application. Acta Oncol 2010;49:851-8
   PubMed Web of Science ®Google Scholar
• Quissak C, Litalien G, Alves M. Cost-effectiveness analysis of dasatinib for the treatment of imatinib resistant or intolerant CML patients in Brazil. Value Health 2008; A64(Abstract)
   Web of Science ®Google Scholar
• Sambrook J, Zou D, Taylor MJ, et al. Cost-effectiveness analysis in Canada of dasatinib versus imatinib for the treatment of chronic myelogenous leukemia in patients with imatinib resistance. Blood (ASH Annual Meeting Abstracts) 2007;110 (Abstract 3328)
   Google Scholar
• Rogers G, Hoyle M, Coon JT, et al. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia: systematic review and economic evaluation. Health Technol Assess 2012;16(22);1-410.
   Web of Science ®Google Scholar
• Loveman E, Cooper K, Bryant J, et al. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib resistant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess 2012;16(23):iii-xiii, 1-137
   PubMedGoogle Scholar
• Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health 2011;14:1057-67
   PubMed Web of Science ®Google Scholar
• Taylor M, Lewis L, Lebmeier M, et al. An economic evaluation of dasatinib for the treatment of imatinib resistant patients with chronic myelogenous leukemia. Value Health 2011;14:A1-A214. Abstract
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-treatment. Blood 2008 Feb 1;111(3):1039-43.
   PubMed Web of Science ®Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Value Health 2012;15:843-50
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication. FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing. US Food and Drug Administration, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm379554.htm. Accessed January 26, 2014
   Google Scholar
• US Food and Drug Administration. Synribo (Omacetaxine): Highlights of prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf. Accessed January 26, 2014
   Google Scholar
• Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154-60
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-50
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276(15):1253-8.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim D-W, Kantarjian H. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:2154-60
   Web of Science ®Google Scholar
• Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014;123:2317-24
   PubMed Web of Science ®Google Scholar
• Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114:4361-8
   PubMed Web of Science ®Google Scholar
• Giles F, Coutre Pl, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107-12
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141-5
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403-12
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome -positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007;109:1556-60
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Lévy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115(18):4136-47
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-12
   PubMed Web of Science ®Google Scholar
• Pavey T, Hoyle M, Ciani O, et al. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess 2012;16(42):iii-iv, 1-277
   Web of Science ®Google Scholar
• Medicare 2014 outpatient payment fee schedule and physician fees. Centers for Medicare & Medicaid Services. Medicare Payment Limits File. 2014
   Google Scholar
• Szabo SM, Davis C, Cortes J, Holoyoake, Levy AR. A multinational study for patient preference values for health states for chronic myelogenous leukemia. Value Health 2010;13(1):103-11
   PubMed Web of Science ®Google Scholar
• Redbook Online [online database]. Greenwood Village, CO: Truven Health Analytics. Accessed January 26, 2014
   Google Scholar
• Clayton B, Fein A, Gleason P, et al. 2013-2014 Prescription drug benefit cost and plan design report. Copayment for specialty at retail 30. Table 13. Average copayment Q20 amounts for four-tier plan designs. 2013. Pharmacy Benefit Management Institute. Available online: https://www.pbmi.com/shop/prescription-drug-benefit-cost-and-plan-designreports/2013-2014-prescription-drug-benefit-cost-plan-designreport/. Accessed January 26, 2014.
   Google Scholar
• Clayton B, Fein A, Gleason P, et al. 2013-2014 Prescription drug benefit cost and plan design report. Overall dispensing fee for branded drugs in specialty pharmacies. Q22 Table 25 Average [Median] dispensing fee by pharmacy channel. 2013. Pharmacy Benefit Management Institute. https://www.pbmi.com/shop/prescription-drug-benefit-cost-andplan-design-reports/2013-2014-prescription-drug-benefit-cost-plandesign-report/. Accessed January 26, 2014.
   Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500
   PubMed Web of Science ®Google Scholar